Journal List > J Korean Ophthalmol Soc > v.51(4) > 1008789

Kim, Jeong, You, and Lee: Effect of Simultaneous Intravitreal Bevacizumab and Retrobulbar Triamcinolone Injection in Refractory Neovascular Glaucoma

Abstract

Purpose

To identify the regression of neovascularization and relief of other symptoms after intravitreal bevacizumab and retrobulbar triamcinolone injection in neovascular glaucoma patients with no possibility of visual acuity recovery.

Methods

A total of 15 eyes in 15 patients with neovascular glaucoma, who had no possibility of visual acuity recovery and could not be treated with surgical intervention despite pain from October 2008 to May 2009, were reviewed retrospectively. Changes in degree of pain, conjunctival injection, revascularization, and visual acuity were evaluated after injection.

Results

Ten of the 15 (67%) neovascular glaucoma patients were male, with a mean age of 62.50±12.79 years. The most common prediposing ocular disease was diabetic retinopathy (9; 60%), and the others were central retinal vein occlusion (4: 26%), central retinal artery occlusion (1; 7%), and uveitis (1; 7%). Change in intraocular pressure was significant (p<0.001), as were decreases in the degrees of pain and conjunctival injection (p<0.001, <0.001) after the injections. Regression of neovascularization continued in 13 patients (87%) after two months.

Conclusions

Intravitreal bevacizumab and retrobulbar triamcinolone injection is a safe intervention that can substantially relieve pain experienced by neovascular glaucoma patients.

References

1. Moraczewsk AL, Lee RK, Palmberg PF, et al. Outcomes of abdominal of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol. 2009; 93:589–93.
2. Kawaji T, Takano A, Inomata Y, et al. Trans tenon's retrobulbar triamcinolone acetonide injection for macular oedema related to branch retinal vein occlusion. Br J Ophthalmol. 2008; 92:81–3.
3. Rodriguez ML, Juarez CP, Luna JD. Intravitreal triamcinolone acetonide injection in blind painful eyes. Eur J Ophthalmol. 2003; 13:292–7.
4. Maeng H, Kim J, Kee C. Intravitreal Bevacizumab injection for the treatment of early stage neovascular glaucoma. J Korean Ophthalmol Soc. 2008; 49:696–700.
5. Allen RC, Bellows AR, Hutchinson BT, Murphy SD. Filtering surgery in the treatment of neovascular glaucoma. Ophthalmology. 1982; 89:1181–7.
6. Heuer DK, Parrish RK II, Gressel MG, et al. 5-fluorouracil and glaucoma filtering surgery. II. A Pilot study. Ophthalmology. 1984; 91:384–94.
7. Song YM, Kim JH. Photodynamic therapy with verteporfin for anterior segment neovascularization in neovascular glaucoma. J Korean Ophthalmol Soc. 2005; 46:1592–6.
8. Hayashi K, Hayashi H. Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch abdominall vein occlusion. Am J Ophthalmol. 2005; 139:972–82.
9. Wada M, Ogata N, Minamino K, et al. Trans tenon's retrobulbar injection of triamcinolone acetonide for diffuse diabetic macular edema. Jpn J Ophthalmol. 2005; 49:509–15.
10. Kato A, Kimura H, Okabe K, et al. Suppression of laser induced choroidal neovascularization by posterior sub tenon abdominal of triamcinolone acetonide. Retina. 2005; 25:503–9.
11. Gheith ME, Siam GA, de Barros DS, et al. Role of intravitreal abdominal in neovascular glaucoma. J Ocul Pharmacol Ther. 2007; 23:487–91.
12. Kim YH, Kim ES, Yu SY, Kwak HW. Long term effect of abdominal bevacizumab for CNV secondary to age related macular degeneration. J Korean Ophthalmol Soc. 2008; 49:1935–40.
13. Chandler DB, Rozakis G, de Juan E Jr, Machemer R. The effect of triamcinolone acetonide on a refined experimental model of abdominal vitreoretinopathy. Am J Ophthalmol. 1985; 99:686–90.
14. Schindler RH, Chandler D, Thresher R, Machemer R. The abdominal of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982; 93:415–7.
15. Mc Cuen BW II, Besslar M, Tano Y, et al. The lack of toxicity of intravitreally administrated triamcinolone acetonide. Am J Ophthalmol. 1981; 91:785–8.
16. Scholes GN, O'Brien WJ, Abrans GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol. 1985; 103:1567–9.
17. Kaushik S, Gupta V, Gupta A, et al. Intractable glaucoma abdominal intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol. 2004; 137:758–60.
18. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003; 136:791–6.
19. Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and abdominal noninfectious endophthalmitis after intravitreal abdominal acetonide injection. Retina. 2003; 23:686–91.
20. McCartney HJ, Drysdale IO, Gornall AG, et al. An autoradio-graphic study of the penetration of subconjunctival injected hy-drocortisone into the normal and inflamed rabbit eye. Invest Ophthalmol. 1965; 4:297–302.
21. Freeman WR, Green RL, Smith RE. Echographic localization of corticosteroids after periocular injection. Am J Ophthalmol. 1987; 103:281–8.S.

Figure 1.
Patient was asked to check the degree of subjective pain using the visual analogue scale at different visiting time (0; no pain, 10; Worst pain that can imagine). (A) Pre-injection time, (B) One week after injection, (C) One month after injection.
jkos-51-568f1.tif
Figure 2.
Change in and grade of conjunctival injection. (A) Pre-injection state (severe conjunctiva vascular con-gestions and epithelial edema; grade 3), (B) After 1 week (grade 2), (C) After 2 months (grade 0).
jkos-51-568f2.tif
Figure 3.
Change in IOP after intravitreal bevacizumab and retrobulbar triamcinolone injection (p<0.001).
jkos-51-568f3.tif
Figure 4.
Change in pain degree after intravitreal bevacizumab and retrobulbar triamcinolone injection (p<0.001).
jkos-51-568f4.tif
Figure 5.
Change in conjunctival injection after intravitreal bevacizumab and retrobulbar triamcinolone injection (p<0.001).
jkos-51-568f5.tif
Figure 6.
Change in neovascularization. (A) Neovascularization on the pupil margin at pre-injection time. (B) Disappearance of neovascularization on the pupil margin and decreasing corneal epithelial edema after 1 week.
jkos-51-568f6.tif
Table 1.
Characteristics of study population
Characteristics Data
Total patients (n*) 15
   Male 10 (67%)
   Female 5 (33%)
Age (y) 62.50±12.79
Cause of Neovascular glaucoma (n)  
   Diabetes Mellitus 9 (60%)
   Central retinal vein occlusion 4 (27%)
   Central retinal artery occlusion 1 (7%)
   Uveitis 1 (7%)
Stage of Neovascular glaucoma (n)  
   Open angle glaucoma 5(34%)
   Closed angle glaucoma§ 10(67%)

* n=Number of patients

y=Years

Open-angle glaucoma: Normal angle structure visible for at least 180°

§ Closed-angle glaucoma: Presence of peripheral anterior synechia for more than 180° or presence of ectropion uvea or presence of hyphema.

Table 2.
Clinical evaluation of BCVA, IOP and neovascularization
Patient Angle BC VA* IOP P (mm Hg)   NVI (2M)
    Pre-injection 2M†† Pre-injection 1M 2M  
1 Closed LPП LP 46 14 15 Regression
2 Open NLP§ NLP 43 5 8 Regression
3 Closed NLP NLP 39 44 46 Regression
4 Closed NLP NLP 32 23 25 Regression
5 Closed NLP NLP 46 33 34 Regression
6 Closed NLP NLP 40 23 21 Regression
7 Closed NLP NLP 48 42 44 Recurrence
8 Closed NLP NLP 47 38 36 Regression
9 Open HM HM 38 34 32 Regression
10 Closed NLP NLP 35 37 35 Regression
11 Open HM# FC**30cm 28 17 15 Regression
12 Closed NLP NLP 52 42 43 Regression
13 Closed NLP NLP 50 30 28 Recurrence
14 Open 0.1 0.1 40 17 15 Regression
15 Open HM 0.1 23 15 14 Regression

* BCVA=best corrected visual acuity

IOP=intraocular pressure

NVI=neovascularization of the iris

§ NLP=non light perception

П LP=light perception

# HM=hand motion

** FC=finger count

†† M=month.

TOOLS
Similar articles